Researchers at the Harvard Wyss Institute have developed an anti-cancer biomaterial treatment that combines adoptive T cell therapy and cancer vaccine technology to treat solid tumors. The researchers have called their technique SIVET, which is short for “synergistic in situ vaccination enhanced T cell”. The approach combines local delivery of (Read more...)